β-synuclein in cerebrospinal fluid as a potential biomarker for distinguishing human prion diseases from Alzheimer’s and Parkinson’s disease
Abstract Background β-synuclein (β-syn), mainly expressed in central nerve system, is one of the biomarkers in cerebrospinal fluid (CSF) and blood for synaptic damage, which has been reported to be elevated in CSF and blood of the patients of prion diseases (PrDs). Methods We analyzed 314 CSF sample...
Saved in:
Main Authors: | Bing Xu, Kang Xiao, Xiaoxi Jia, Rundong Cao, Donglin Liang, Ruhan A, Weiwei Zhang, Chunjie Li, Liping Gao, Cao Chen, Qi Shi, Xiaoping Dong |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2025-02-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-025-01688-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Refining α-synuclein seed amplification assays to distinguish Parkinson’s disease from multiple system atrophy
by: James A. Wiseman, et al.
Published: (2025-02-01) -
Unmet needs of biochemical biomarkers for human prion diseases
by: Peter Hermann, et al.
Published: (2024-12-01) -
Novel method for classification of prion diseases by detecting PrPres signal patterns from formalin-fixed paraffin-embedded samples
by: Sachiko Koyama, et al.
Published: (2024-12-01) -
Prion meeting 2023: implications of a growing field
by: Tiago F. Outeiro, et al.
Published: (2024-12-01) -
Rosa moschata ameliorates haloperidol-induced Parkinson's disease via reduction of neurodegeneration and oxidative stress
by: Badriyah S. Alotaibi, et al.
Published: (2025-01-01)